Creo Medical Group plc has completed a US$15.7 million equity fundraise
October 2024 — Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Creo Medical develops minimally invasive electrosurgical devices designed to improve patient outcomes. With its innovative CROMA and Kamaptive technologies, Creo Medical is setting new standards in precision and flexibility for clinicians across a range of surgical procedures. This funding has been sought to mitigate the completion risk of its recently announced sale of a 51% controlling interest in the group’s European subsidiary, Creo Medical Europe. It also aims to provide balance sheet strength for future growth, as Creo Medical continues to roll out its defined medtech strategy.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, served as advisor to Creo Medical on the transaction.
Talk to the deal team
Related deals
Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn moreRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Learn more